Does the corrected option share count affect Skye Bioscience’s prior disclosures?

The amendment only updates the stated total of repriced option shares. The company notes that no other part of the original report was modified, so all other previously disclosed terms and information remain as originally presented in that earlier Form 8-K.

Skye Bioscience (SKYE) fixes share count for repriced stock options

Q: How many Skye Bioscience shares are underlying the repriced options?

The company states that 2,458,158 shares of its common stock underlie all repriced options. This figure corrects an earlier misstatement and represents the updated total covered by the option repricing arrangement described in the original Form 8-K.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K/A

Rhea-AI Filing Summary

Skye Bioscience, Inc. filed an amended current report to correct a clerical error in an earlier disclosure about stock options. The company now states that the total number of shares of common stock underlying all repriced options is 2,458,158 shares. No other aspects of the prior report were changed.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Repriced options underlying shares: 2,458,158 shares

1 metrics

Repriced options underlying shares 2,458,158 shares Total common shares underlying all repriced options

Key Terms

Form 8-K/A, Option Repricing, Repriced Options, Emerging growth company

4 terms

Form 8-K/A regulatory

"FORM 8-K/A Pursuant to Section 13 or 15(d)"

A Form 8-K/A is an amended current report filed with the U.S. Securities and Exchange Commission to correct, clarify or add information that was previously disclosed on a Form 8-K about a material corporate event. For investors it matters because it updates the official record—like an edited breaking-news bulletin—so market participants can reassess a company’s risks, valuation or legal exposure based on the most accurate, complete information.

Option Repricing financial

"Item 5.02 ... Compensatory Arrangements of Certain Officers. Option Repricing"

Repriced Options financial

"shares of common stock of the Company underling all Repriced Options"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

04/06/2026 - 04:10 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 31, 2026

SKYE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55136

45-0692882

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)


11250 El Camino Real, Suite 100, San Diego, CA 92130
(Address of principal executive offices)


(858) 410-0266
(Registrant’s telephone number, including area code)

_________________________


(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Current Report on Form 8-K/A (this “Amendment”) is being filed as an amendment to the Current Report on Form 8-K filed by Skye Bioscience, Inc. (the “Company”) with the Securities and Exchange Commission on April 3, 2026 (the “Original Report”). The sole purpose for filing this Amendment is to correct a scrivener’s error (the “Specified Error”) describing the total number of shares of common stock of the Company underlying all Repriced Options (as defined in the Original Report). This Amendment supplements the Original Report and should be read in conjunction with the Original Report. No other changes have been made to the Original Report other than to correct the Specified Error, as described above and reflected below.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Option Repricing

The total number of shares of common stock of the Company underling all Repriced Options is 2,458,158 shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


SKYE BIOSCIENCE, INC.


Dated: April 6, 2026			/s/ Punit Dhillon
			Name: Punit Dhillon
			Title: President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Skye Bioscience (SKYE) change in this Form 8-K/A?

Skye Bioscience filed an amended report to fix a clerical error in its prior option repricing disclosure. It clarified the correct total number of common shares underlying all repriced options, without making any other changes to the original report.

How many Skye Bioscience shares are underlying the repriced options?

The company states that 2,458,158 shares of its common stock underlie all repriced options. This figure corrects an earlier misstatement and represents the updated total covered by the option repricing arrangement described in the original Form 8-K.

Does this Skye Bioscience 8-K/A introduce any new compensation arrangements?

No, the amendment does not introduce new compensation arrangements. It only corrects the number of common shares underlying all previously described repriced options, leaving all other terms and disclosures from the original report unchanged as filed earlier.

Why did Skye Bioscience file an amendment to its 8-K on option repricing?

Skye Bioscience filed the amendment to correct a scrivener’s error in the earlier filing. The error related to the total number of common shares tied to the repriced options, which is now disclosed as 2,458,158 shares to accurately match the underlying awards.

Filing Exhibits & Attachments

3 documents